Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 5;230(2):e405–e415. doi: 10.1093/infdis/jiad434

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Higher magnitude-breadth in vaccinees who received the AS01_B adjuvant. Magnitude-breadth of antibody-dependent T-cell-mediated cytotoxicity responses measured by (A and B) GranToxiLuc and (C and D) luciferase. Samples from the participants collected at 2 weeks after the last vaccination (month 6.5; A and C) and 6 months after the last vaccination (month 12; B and D) were tested against HIV1 subtype C 96ZM651 gp120, 1086 B2 gp120, and subtype C TV1 gp120. Treatment groups are 200 µg Pr + MF59, 200 µg Pr + AS01_B, 40 µg Pr + AS01_B, and placebo. Abbreviations: gp, glycoprotein; Pr, protein.